Natixis Advisors LLC Decreases Stock Holdings in The Chemours Company (NYSE:CC)

Natixis Advisors LLC lowered its stake in The Chemours Company (NYSE:CC - Free Report) by 27.9% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 377,973 shares of the specialty chemicals company's stock after selling 146,232 shares during the quarter. Natixis Advisors LLC owned 0.25% of Chemours worth $7,680,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Matrix Trust Co purchased a new position in shares of Chemours in the third quarter valued at approximately $25,000. Blue Trust Inc. lifted its holdings in Chemours by 166.9% in the 3rd quarter. Blue Trust Inc. now owns 1,169 shares of the specialty chemicals company's stock valued at $26,000 after purchasing an additional 731 shares in the last quarter. New Covenant Trust Company N.A. acquired a new stake in Chemours during the 1st quarter worth $29,000. Signaturefd LLC boosted its stake in Chemours by 163.7% during the 3rd quarter. Signaturefd LLC now owns 1,959 shares of the specialty chemicals company's stock worth $40,000 after purchasing an additional 1,216 shares during the last quarter. Finally, Itau Unibanco Holding S.A. purchased a new stake in shares of Chemours during the second quarter worth $58,000. Hedge funds and other institutional investors own 76.26% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Morgan Stanley lowered their price target on shares of Chemours from $30.00 to $25.00 and set an "equal weight" rating on the stock in a research report on Tuesday, November 5th. Barclays lifted their price objective on Chemours from $21.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Tuesday, November 5th. BMO Capital Markets upped their price objective on shares of Chemours from $30.00 to $32.00 and gave the company an "outperform" rating in a report on Monday, October 7th. Royal Bank of Canada reduced their target price on shares of Chemours from $28.00 to $25.00 and set an "outperform" rating on the stock in a research note on Wednesday, November 6th. Finally, UBS Group decreased their target price on shares of Chemours from $30.00 to $28.00 and set a "buy" rating on the stock in a report on Tuesday, August 6th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, Chemours currently has a consensus rating of "Hold" and an average price target of $24.88.

Insider Buying and Selling

In other Chemours news, SVP Alvenia Scarborough sold 7,500 shares of the stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $20.64, for a total value of $154,800.00. Following the sale, the senior vice president now owns 16,645 shares of the company's stock, valued at $343,552.80. This trade represents a 31.06 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.47% of the stock is owned by insiders.

Chemours Trading Up 3.5 %

Shares of Chemours stock traded up $0.73 on Friday, reaching $21.53. The company had a trading volume of 1,708,016 shares, compared to its average volume of 1,578,085. The firm's 50 day moving average price is $19.32 and its two-hundred day moving average price is $21.61. The company has a debt-to-equity ratio of 6.05, a quick ratio of 0.92 and a current ratio of 1.73. The Chemours Company has a 52-week low of $15.10 and a 52-week high of $32.70. The firm has a market cap of $3.22 billion, a PE ratio of 43.06 and a beta of 1.75.

Chemours (NYSE:CC - Get Free Report) last posted its earnings results on Monday, November 4th. The specialty chemicals company reported $0.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.32 by $0.08. The firm had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.44 billion. Chemours had a return on equity of 29.48% and a net margin of 1.34%. Chemours's revenue was up .9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.64 EPS. Sell-side analysts predict that The Chemours Company will post 1.35 earnings per share for the current fiscal year.

Chemours Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 16th. Investors of record on Friday, November 15th will be issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a dividend yield of 4.64%. The ex-dividend date of this dividend is Friday, November 15th. Chemours's dividend payout ratio (DPR) is currently 200.00%.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.